Autolus Therapeutics plc
Biopharmaceutical company developing programmed T cell therapies for cancer and autoimmune diseases.
AUTL | US
Overview
Corporate Details
- ISIN(s):
- US05280R1005
- LEI:
- Country:
- United States of America
- Address:
- THE MEDIAWORKS, LONDON
- Website:
- https://www.autolus.com/
- Sector:
- Manufacturing
Description
Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing next-generation, programmed T cell therapies for cancer and autoimmune diseases. The company specializes in Chimeric Antigen Receptor (CAR) T-cell technology, which reprograms a patient's own T cells to recognize and eliminate disease cells. Its lead therapy, obecabtagene autoleucel (obe-cel), is approved for the treatment of adult relapsed/refractory B-cell Acute Lymphoblastic Leukemia (ALL). Autolus leverages its advanced cell programming capabilities and proprietary manufacturing processes to develop a pipeline of precise and controlled autologous therapies targeting hematological malignancies, solid tumors, and autoimmune conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Autolus Therapeutics plc filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Autolus Therapeutics plc
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Autolus Therapeutics plc via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
